• Publications
  • Influence
Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin.
Ghrelin is a peptide predominantly produced by the stomach. Ghrelin displays strong GH-releasing activity. This activity is mediated by the activation of the so-called GH secretagogue receptor typeExpand
  • 1,143
  • 53
  • PDF
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
CONTEXT Although considerable data exist on the use of long-acting somatostatin analogs to treat acromegaly, their reported efficacy differs substantially among trials. OBJECTIVE We conducted aExpand
  • 321
  • 21
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
BACKGROUND Patients with acromegaly are currently treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverseExpand
  • 436
  • 20
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans.
Ghrelin possesses strong GH-releasing activity but also other endocrine activities including stimulation of PRL and ACTH secretion, modulation of insulin secretion and glucose metabolism. It isExpand
  • 347
  • 16
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-releaseExpand
  • 253
  • 16
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans.
Ghrelin, a 28 amino acid gastric hormone is a natural ligand of the GH Secretagogue (GHS) receptor (GHS-R) and strongly stimulates GH secretion though, like synthetic GHS, it shows other endocrineExpand
  • 693
  • 13
Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.
Five somatostatin receptor (sst) subtype genes, sst(1), sst(2), sst(3), sst(4) and sst(5), have been cloned and characterised. The five sst subtypes all bind natural somatostatin-14 andExpand
  • 182
  • 12
  • PDF
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
CONTEXT/OBJECTIVE Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral alkylating drug withExpand
  • 106
  • 10
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
CONTEXT Pegvisomant is a GH receptor antagonist. The ACROSTUDY is a global safety surveillance study of long-term treatment of acromegaly with pegvisomant. OBJECTIVE The objective of the study wasExpand
  • 196
  • 9
Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a.
Recent studies demonstrate widespread expression of ghrelin among tissues and have uncovered its pleiotropic nature. We have examined gene expression of ghrelin and its two receptor splice variants,Expand
  • 146
  • 9
  • PDF